Skip to main content
Fig. 1 | Allergy, Asthma & Clinical Immunology

Fig. 1

From: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Fig. 1

Study design and assessments. a Time from Ig20Gly initiation. Cohort 1 transitioned to Ig20Gly at study enrollment; Cohort 2 transitioned to Ig20Gly approximately 6 months prior to enrollment; and Cohort 3 transitioned to Ig20Gly approximately 12 months prior to enrollment. Ig20Gly, Immune Globulin Subcutaneous (Human) 20% solution; IgG, immunoglobulin G; SCIG, subcutaneous immunoglobulin

Back to article page

Allergy, Asthma & Clinical Immunology

ISSN: 1710-1492

Contact us